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ABSTRACT  
Background: Bone marrow is a frequent site of metastatic tumors, especially from breast, lung, 
and prostate cancers.  Metastatic tumor in the bone marrow may influence the response to 
treatment, overall survival, and resulting decreased hematopoiesis. Diffusely and homogenously 
bone marrow uptake in 18F-FDG PET/CT scan is frequently observed which can caused by many 
conditions. Material and methods: We retrospectively analyzed the consecutive records of F-
18 FDG PET scans performed from April 2011 to August 2013 at Mochtar Riady Comprehensive 
Cancer Center Siloam Hospital, A total of 2952 result were reviewed. 16 patients with diffusely 
and homogenously bone marrow uptake in F-18 FDG PET/CT whole body scan between January 
2012 and December 2013 were evaluated to find out the etiology. Results: From 2952 patients 
performed 18F-FDG-PET/CT there are 16 patients (5 men, 11 women) with diffusely and 
homogenously increased FDG uptake in bone marrow, mean age: 52 years, range 5–82 years. It 
was found that 6 of 16 FDG PET/ CT positive patient with solid tumors and 10 of 16 FDG PET/CT 
with nonsolid tumors.  Malignancy was observed in 14 patients and benign in 2 patients. 
Diffusely and homogenously uptake due to 1 patiets with Idiopathic thrombocytopenic purpura  
(ITP) , 6 patient with anaemia, 7 patients with chemotherapy, 1 patients with Granulocyte 
Colony-Stimulating Factor (G-CSF) and 1 patients with extra-nodal non-hodgkin lymphoma were 
observed. Conclusion: Diffusely and homogenously increase bone marrow on 18F FDG PET/ CT 
whole body scan uptake can be seen in malignant or benign disease and history of treatment. 
Spleen uptake are observed at the initial imaging than bone marrow involvement while spleen 
uptake more frequently reflects disease involvement. 
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INTRODUCTION 
The International Agency for Research on Cancer (IARC), the 
specialized cancer agency of the World Health Organization, 
released the latest data on cancer incidence, mortality, and 
prevalence worldwide including Indonesia.  According to 
GLOBOCAN 2012, an estimated 14.1 million new cancer cases 
and 8.2 million cancer-related deaths occurred in 2012. The 
most commonly diagnosed cancers worldwide were those of 
the lung (1.8 million, 13.0% of the total), breast (1.7 million, 
11.9%), and colorectum (1.4 million, 9.7%). The most common 
causes of cancer death were cancers of the lung (1.6 million, 
19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 
million, 8.8%). [1]  
Bone marrow (BM) is one of the most common sites to be 
involved by tumors that metastasize via the bloodstream.[2] 
Bone marrow is a frequent site of metastatic tumors, 
especially from breast, lung, and prostate cancers. 
Approximately 90% of metastases have been observed in 
concordance with the distribution of hematopoietic 
marrow.[3] Detection of metastatic tumors to the bone 
marrow is of great importance for the clinical staging of tumor 
spread because malignant infiltration of hematopoietic tissue 
can alter the clinical course of the disease. Metastatic tumor 
in the bone marrow may influence the response to treatment, 
overall survival, and resulting decreased hematopoiesis. The 
bone marrow provides erythrocytes, leukocytes, and platelets 
to the body, and usually accumulates small amount of F-18 
fluoro-2-deoxyglucose (F-18 FDG) on positron emission 
tomography (PET) images. Bone marrow hypermetabolism 
might reflect characteristics of the neoplasm, although 
cytokines are produced not only by neoplasm but also as part 
of the inflammatory response.[2,5]  Though bone marrow 
involvement is most commonly seen with myeloid or 
lymphoid hematological malignancies, solid tumors may also 
spread to the bone maroow  via the hematogenous route.[2] 
Many imaging modalities have been developed to detect and 
assess bone marrow metastases.[2] Positron-emission 
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tomography (PET) using 2-fluorine 18-fluoro-2-deoxy-D-
glucose (FDG) and other metabolic tracers has been shown to 
be a useful modality to stage malignant tumors and evaluate 
the efficacy of treatment.   18F-fluorodeoxyglucose (FDG) 
positron emission tomography (PET) or 18F-FDG 
PET/computed tomography (CT) is widely used for the 
diagnosis, staging, and response assessment of various types 
of malignancy.[4]  
Few data are available regarding the diagnostic impact of 18F-
FDG PET diffuse bone marrow uptake seen not rarely at initial 
staging of patients with hodgkin lymphoma in particularly for 
bone marrow involvement.[5,6]. However differentiating 
diffuse increase in bone marrow F-18 FDG uptake, 
attributable to the involvement of malignancy or 
hematopoietic disease from other causes, such as the 
administration of hematopoietic cytokines or the 
inflammatory response is important.[5] The aim of this 
retrospective study was to describe the etiology of increased 
hypermetabolism diffusely dan homogeneous bone marrow 
FDG uptake. In the same way diffuse splenic uptake (SU) is 
frequently observed at initial staging too and its significance 
has not been clarified. 
MATERIAL AND METHODS 
Patients 
We retrospectively analyzed the consecutive records of F-18 
FDG PET scans performed from April 2011 to August 2013 at 
Mochtar Riady Comprehensive Cancer Center Siloam 
Hospital, A total of 2952 results were reviewed. We selected 
patients with FDG uptake in bone marrow. The criteria 
inclusion was homogenously and diffusely increased bone 
marrow FDG uptake with higher than liver background.  The 
exclusion criteria were focals uptake in bone marrow. The 
analysis included 16 patients with diffusely and 
homogenously increased bone marrow FDG uptake on PET/CT 
whole body scan between January 2012 and December 2013 
were evaluated to find out the etiology. The patient profile is 
summarized in Table 1. 
Imaging 
Patients were injected intravenously with 185–370 MBq (5–
10 mCi) of 18F-FDG at least 6 hours after the fasting period for 
18F-FDG PET-CT imaging. Approximately one hour after 
injection (40- 60 min), the patient rested in a reclining chair in 
a quiet room between the tracer injection and the start of 
PET/CT image acquisition. PET-CT scanning was performed 
from the head to the proximal thigh using a clinical PET-CT 
system. 
Table 1. Clinical characteristic of the patients 
Sex N % 
Male 5 37 
Female 11 63 
Diagnosis   
Lymphoma 5 30 
Cervic Ca 2 12 
Thalasemia Mayor 1 6 
Anaemia And Vena Porta Trombosis 1 6 
Lymphoma Non Hodkin 3 18 
Tongue Ca 1 6 
Breast Ca 3 18 
STATISTICAL ANALYSIS 
Descriptive statistics used. 
RESULTS 
Patient characteristics 
From 2952 patients performed 18F-FDG-PET/CT there are 16 
patients (5 men, 11 women) with diffusely and homogenously 
increased FDG uptake in bone marrow, mean age: 52 years, 
range 5–82 years.   It was found that 6 of 16 FDG PET/ CT 
positive patient with solid tumors and 10 of 16 FDG PET/CT 
with non solid tumors.  
The solid tumours considered breast cancer in 3 patients, 
Carcinoma Cervic in 2 patients and tongue cancer in 1 
patients. The non-solid tumours considered Hodgkin 
lymphoma in 5 patients, Thalasemia Mayor in 1 patient, 
Anaemia and Vena Porta Trombosis in 1 patients and 
Lymphoma Non Hodkin in 3 patients.  
Diffuse uptake from solid tumours and non-solid tumours 
caused diagnosed by Idiopathic thrombocytopenic purpura 
(ITP), anaemia, post chemotherapy, extra nodule Non 
Hodgkin Lymphoma and Granulocyte Colony-Stimulating 
Factor (GCSF). There is one patient with non solid tumor cause 
by ITP, 2 patients with solid tumours and 4 patients with non 
solid tumour cause by anaemia, 4 patients with solid tumours 
and 3 patients from non solid tumours cause by post 
chemotherapy, 1 patients with non solid tumour cause by 
extranodule Lynphoma non Hodgkin and 1 patients with non 
solid tumours cause by after giving Granulocyte Colony-
Stimulating Factor. 6/16 subjects come with solid tumour and 
11/16 with non solid tumour. 
Table 2. Cause of diffusely and homogeneous FDG uptake in 
the bone marrow. 
Kind of 
Tumour 
Cause 
IT
P 
Ana
emia 
Chemothe
rapy 
Extranodule 
LNH 
GCSF 
Solid  2 4   
Non Solid 1 4 3 1 1 
 
PET/CT results 
 
Criteria to assess positivity for bone marrow involvement on 
FDG PET/CT were either diffusely and homogeneous FDG 
uptake in the bone marrow higher than in the liver.  PET/CT 
results were classified by cause diagnosed like ITP, Anaemia, 
Chemotherapy, Extranodule LNH, and GCSF.  PET/CT was 
reported as diffuse uptake bone marrow in 16 patients. All of 
these patients also had negative uptake focal in bone. 
Maximum intensity projection (MIP) seen and SU (splenic 
uptake) was visually graded according to liver uptake:  
 
1. Bone marrow FDG uptake can be caused by post 
chemotherapy seen diffusely and homogenously 
increase bone marrow on 18F FDG PET/ CT whole 
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body scan uptake. No uptake pathologis in other 
places. 
2. Same as post-chemotherapy, bone marrow FDG 
uptake can be caused by anaemia seen diffusely and 
homogenously increase bone marrow on 18F FDG 
PET/ CT whole body scan uptake. Slowly increased 
FDG activity in the splenic uptake. 
3. Bone marrow FDG uptake can be caused by 
Extranodal Lymphoma Hodgkin’s seen diffusely and 
homogenously increase bone marrow on 18F FDG 
PET/ CT whole body scan uptake.  Increased FDG 
activity in the splenic uptake. 
4. Bone marrow FDG uptake can be caused by 
Granulocyte Colony-Stimulating Factor (G-CSF) seen 
diffusely and homogenously increase bone marrow 
on 18F FDG PET/ CT whole body scan uptake. Slowly 
increased FDG activity in the splenic uptake. 
            Post- Chemotherapy                      Anaemia                
                                                        SU higher than liver uptake    
                     Extranodal LH                        G-CSF 
    SU higher than 
             liver uptake                   
 
Figure . FDG-PET/CT defined bone marrow involvement as 
diffusely and homogenously bone marrow uptake caused 
by many conditions 
 
DISCUSSION 
Positron emission tomography using 18F-fluorodeoxyglucose 
(FDG-PET) has come to be recognized as a useful modality for 
tumor imaging, which is based on the elevated glucose 
metabolism in tumor cells. Correlations have been reported 
between 18F-FDG uptake by the bone marrow and the 
peripheral blood neutrophil count.[7]  The bone marrow (BM) 
provides erythrocytes, leukocytes, and platelets to the body, 
and usually accumulates small amount of F-18 fluoro-2-
deoxyglucose (F-18 FDG) on positron emission tomography 
(PET) images. Differentiating a diffuse increase in the BM F-18 
FDG uptake, attributable to the involvement of malignancy or 
hematopoietic disease from other causes, such as the 
administration of hematopoietic cytokines or the 
inflammatory response, is important. Although the above-
mentioned studies showed correlations between the bone 
maarow F-18 FDG uptake and age, hematological parameters 
or blood cytokine levels using groups of patients, the intensity 
of the bone barrow  F-18 FDG uptake seems to have been 
determined subjectively as diffusely increased to make the 
diagnosis for individual patients.[8] 
During the past decade, a large body of evidence has 
confirmed the importance of positron emission tomography 
(PET) using 2-[18F]-fluoro-2-deoxy-D -glucose (FDG) as a 
diagnostic tool in the evaluation of malignant lesions, 
including lymphoma. Bone marrow is a frequent site of 
lymphoma involvement and of metastatic tumors from 
breast, lung, and prostate cancers.[9] The diffuse increase in 
FDG uptake in the bone marrow not only may be caused by 
malignancy or hematopoietic disease, but also may be due to 
an inflammatory reaction, recent chemotherapy, or 
administration of hematopoietic growth factors.  A diffuse 
increase in FDG uptake has also been reported in hyperplastic 
bone marrow with or without cytokine therapy.[11]  At a glance 
these findings are not compatible with the prior study that 
showed no change in the bone marrow uptake after a few 
cycles of chemotherapy.[10] However, our findings are 
consistent with previously reported bone marrow reserve 
after chemotherapy. 
Hodgkin’s Lymphoma is highly FDG avid. Diffusely and 
homogeneous bone marrow uptake over the axial skeleton 
and proximal appendicular skeleton is not a pattern of BMI in 
Hodgkin’s disease and is due to inflammation and effect on 
bone marrow driven by cytokine release.(9)  Since Hodgkin 
and aggressive non-Hodgkin lymphomas show an intense 
glucose metabolism and therefore a high FDG uptake. FDG 
PET/CT can be helpful in both nodal and extra-nodal staging 
of lymphoma, including the bone marrow assessment. Criteria 
to assess positivity for bone marrow involvement on FDG 
PET/CT in patients with Hodgkin lymphoma may vary from 
one study to another: bone marrow FDG uptake higher than 
the liver, focal, multi-focal or abnormally increased FDG 
uptake, or bone marrow FDG uptake higher than the 
mediastinal blood pool as reference.[12] Diffuse SU (without 
focus) could reflect lymphoma infiltrationbut could reflect 
activation and proliferation of macrophages as observed after 
granulocyte colony-stimulating factor (G-CSF).[6] 
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Despite excellent performance in bone marrow staging in 
both Hodgkin and non-Hodgkin lymphomas, FDG PET/CT 
false-positive findings may occur, especially when diffuse 
bone marrow and splenic uptake are observed at the initial 
imaging. As demonstrated by Salaun et al.[13] diffuse bone 
marrow uptake is more likely to be due to inflammatory 
changes than bone marrow involvement, while splenic uptake 
more frequently reflects disease involvement.[12] But this 
pattern was differentiated from diffuse homogeneously 
increased uptake in the skeleton, which is often seen in HL 
patients at staging and in most cases is due to paraneoplastic 
bone marrow activation and not to diffuse BMI by HL.[14] The 
presence of extranodal involvement is very important for 
staging NHL and HL. In general, extranodal involvement is 
more common in NHL than in HL, while it is frequently 
observed in recurrent disease and immune deficiency-related 
lymphomas. Primary and secondary extranodal diseases have 
different prognostic implications.Lymphomas that initially 
appear to have the bulk of the disease at extranodal sites are 
described in primary extranodal lymphoma and categorized 
as stage I or II. [15] The pattern of the FDG uptake in the bone 
marrow sites is directly dependent on the pattern of 
infiltration of the marrow by the disease. Lymphomas may 
often manifest one or a mixture of the focal (involving one or 
more areas), diffuse (replacing the adipose tissue and 
hematopoietic elements), or dispersed (in the form of single 
or a limited number of neoplastic cells distributed in between 
the hematopoietic elements) patterns irrespective of the 
topographical location.[16] 
In this study, FDG uptake was significantly increased in 
patients treated with G-CSF. Granulocyte colony-stimulating 
factor (G-CSF) is hematopoietic cytokines that regulate 
proliferation and differentiation of hematopoietic progenitor 
cells in the bone marrow. Human G-CSF has been produced 
by recombinant DNA technology, and exogenous 
administration of these factors has been shown to increase 
circulating neutrophil levels dramatically. G-CSF has been 
used increasingly to prevent chemotherapy-induced 
infections.  With the increasing use of cytokine therapy and of 
FDG PET for the assessment of the efficacy of chemotherapy, 
increased FDG uptake in normal bone marrow during and 
after cytokine therapy.   This increased uptake in normal bone 
marrow during and after G-CSF may mimic progressive bone 
or bone marrow metastases, and metastatic lesions may be 
obscured by the elevated FDG accumulation in the bone 
marrow. Hematopoietic CSFs have been used to treat the 
myelo suppressive effects of chemotherapy since the 1990s 
G-CSF has been used to stimulate differentiation and 
production of progenitor cells. In clinical studies, G-CSF has 
been shown to significantly reduce the duration of 
neutropenia. GCSF has also been identified as a cause of 
increased bone FDG uptake.[10] Because normal bone marrow 
usually shows only a minor amount of FDG uptake, increased 
FDG uptake may resemble bone marrow metastases or make 
true metastatic lesions difficult to see. It was shown that a 
substantial increase in bone marrow FDG uptake is rapidly 
induced by colony stimulating factor treatments and should 
not be misinterpreted as diffuse bone metastases or bone 
marrow disease.[11] 
CONCLUSION 
The pattern of bone marrow uptake in oncological cases could 
be diffuse, focal, or mix. Diffusely and homogenously increase 
bone marrow uptake on 18F FDG PET/ CT whole body scan can 
be seen in malignant or benign disease and history of 
treatment. Spleen uptake observed at the initial imaging than 
bone marrow involvement while spleen uptake more 
frequently reflects disease involvement.  
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